Navigation Links
Sirion Therapeutics Supports Ophthalmic Education

- Company Provides Unrestricted Educational Grants to Support the 25th

Biennial Cornea Research Conference and the Inaugural DIRECT Dry AMD

Meeting -

TAMPA, Fla., Sept. 28 /PRNewswire/ -- Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, today announced its support of the advancement of ocular innovation through its contributions of unrestricted educational grants to two upcoming ophthalmology conferences.

The first conference is Harvard University's Schepens Eye Research Institute's 25th Biennial Cornea Research Conference, taking place October 12 and 13, 2007 in Boston, MA. Schepens is the largest independent eye research institute in the nation, and an affiliate of Harvard Medical School. For additional information on this meeting, please visit their website at

The second contribution will benefit the Duke University School of Medicine's Inaugural DIRECT Dry AMD Meeting, taking place October 25-27, 2007 in Durham, NC. This conference will update attendees with the latest information on Dry Age-related Macular Degeneration (AMD). For additional information on this meeting, please visit their website at

"Both of these conferences play a vital role in the awareness and advancement of research in ophthalmology," said Barry Butler, Sirion's President and Chief Executive Officer. "We appreciate the opportunity to support these institutions in advancing the treatment of ophthalmic disease."

About Sirion Therapeutics, Inc.

Sirion Therapeutics is a privately held biopharmaceutical company pursuing the discovery, development and commercialization of products addressing unmet medical needs in the protection and preservation of eyesight. Sirion's pipeline includes four late-stage opportunities: ganciclovir, a topical antiviral for herpetic keratitis which is awaiting an NDA filing in early 2008; difluprednate, a potent topical steroid in Phase III development for post-operative inflammation and uveitis; cyclosporine, a topical immunomodulator in Phase III testing for dry eye and fenretinide, a first-in-class oral vitamin A binding protein antagonist in Phase II development for geographic atrophy associated with dry AMD. For more information regarding Sirion, please visit Sirion's website at

SOURCE Sirion Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. CDW buyer supports Berbee growth plans
3. Tech center supports energy-saving device for heat-treating plants
4. Inacom Supports Blackhawk Technology Mentor Program
5. Computer Card Supports Solo Doctor
6. Federal Funding Supports Small Business Innovation
7. Doyle urges support of higher education spending
8. Jump starting technology education
9. Stem cell and regenerative medicine center to aid education and commerce
10. Education is fundamental to Milwaukees growth
11. New book touts educational power of computer games
Post Your Comments:
(Date:11/25/2015)... -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... Neurocrine Biosciences, will be presenting at the 27th Annual ... . .   Listeners ... prior to the presentation to download or install any ... available on the website approximately one hour after the ...
(Date:11/25/2015)... 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; ... and prospects remain fundamentally strong and highlights the ... recently received DSMB recommendation to continue the ZoptEC ... of the final interim efficacy and safety data ... in men with heavily pretreated castration- and Taxane-resistant ...
(Date:11/25/2015)... IN (PRWEB) , ... November 25, 2015 , ... ... (AMA) and the Organization of Black Aerospace Professionals (OPBAP) has been formalized with ... and other AMA team leaders met with OPBAP leaders Capt. Karl Minter and ...
(Date:11/25/2015)... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) ... chat discussion at the Piper Jaffray 27th Annual Healthcare ... discussion is scheduled for Wednesday, December 2, at 8:00 ... replay will be available for 14 days after the ... NormartVP, Corporate Communications and Business Development , BrewLife(858) 875-8629 ...
Breaking Biology Technology:
(Date:11/20/2015)... Connecticut , November 20, 2015 ... authentication company focused on the growing mobile commerce market ... CEO, Gino Pereira , was recently interviewed on ... interview will air on this weekend on Bloomberg ... Latin America . --> NXTD ) ("NXT-ID" ...
(Date:11/19/2015)... , Nov. 19, 2015  Based on its ... & Sullivan recognizes BIO-key with the 2015 Global Frost ... year, Frost & Sullivan presents this award to the ... catering to the needs of the market it serves. ... line meets and expands on customer base demands, the ...
(Date:11/19/2015)... , Nov. 19, 2015  Although some 350 ... is dominated by a few companies, according to Kalorama ... own 51% of the market share of the 6.1 ... The World Market for Molecular Diagnostic s . ... "The market is still controlled by one company and ...
Breaking Biology News(10 mins):